Jose Lutzky

Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC).

Patrick Schöffski, Keith Steele, J. Nemunaitis, 2015 .

Serial Monitoring of Circulating Tumor Cells Predicts Outcome of Induction Biochemotherapy plus Maintenance Biotherapy for Metastatic Melanoma

Jon Richards, Michael B Atkins, M. Atkins, 2010, Clinical Cancer Research.

Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.

Axel Hoos, Alessandro Testori, Jon Richards, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.